Semaglutide, Tirzepatide, and MICC injections represent a new wave of innovative treatments offering significant benefits for individuals grappling with obesity and related health issues.
GLP-1 and GIP are the primary hormones released in the intestine during food consumption. By blocking receptors and stimulating the pancreas to release insulin, glucose levels are reduced and appetite suppressed.
Derived from a diabetes medication, Semaglutide has demonstrated impressive weight loss effects by regulating appetite and food intake. Clinical trials show substantial reductions in body weight. In many trials, clients taking Semaglutide have been shown to lose up to 10% of their body weight.
Originally developed for diabetes management, Tirzepatide has shown remarkable weight loss outcomes by controlling blood sugar levels and suppressing appetite through multiple pathways. Tirzepatide also boasts an average of 20% weight loss in comparative studies.
Designed to enhance weight loss by increasing metabolic processes and energy levels.
These advancements in pharmacotherapy provide a much needed breakthrough in options for those seeking effective weight management tools. Alongside diet and exercise, thousands have already achieved their weight loss goals. Nonetheless, these medications necessitate careful medical oversight due to potential side effects and individual health considerations.
Class of Medication:
Glucagon-like peptide-1 receptor agonist (GLP-1)
Semaglutide was first brought to market in 2012 under the brand names Ozempic® and Wegovy®. Initially used to treat diabetes, this class of medication has grown a reputation for its remarkable weight loss attributes. So much so, the Food and Drug Association (FDA) has approved Semaglutide for weight loss. Semaglutide works in 3 key ways to facilitate reduction in blood sugars (improving Diabetes) and weight loss.
Class of Medication: Glucose-dependent insulinotropic polypeptide-1 (GIP) and Glucagon-like peptide-1 receptor agonist (GLP-1)
Tirzepatide, first put on the market in 2022 under the brand name Mounjaro® acts in a similar manner to Semaglutide with the added benefit of a GIP. Tirzepatide was recently approved by the FDA for treatment of weight loss.
Common Side Effects of Semaglutide and Tirzepatide
Nausea, Vomiting, Diarrhea, Constipation, Abdominal Pain (Bloating), Indigestion, Low Blood Sugar Levels
Class of Medication: Glucagon-like peptide-1 receptor agonist (GLP-1)
Methionine
Inositol
Choline
Vitamin B12
MICC serves as a beneficial addition to diet and exercise routines with its combination of ingredients promoting weight loss. Results typically become noticeable after three weeks, with an average weight loss of 1-2 lbs per month.
Vitamin B12 is considered an essential vitamin. Fortunately we get this in many of the foods we eat such as; meat, fish, eggs, and dairy products. Low levels can cause a variety of symptoms, some are listed below:
During your weight loss journey Vitamin B12 can give you a boost with increased energy and focus.
